Emgrast M – Recombinant Human Injection
RECOMBINANT HUMAN (EMGRAST-M) INJECTION – TREATMENT FOR PREVENTION OF INFECTIONS AFTER CHEMOTHERAPY
Following chemotherapy, Emgrast M 500mcg Injection is used to prevent infections. It is a growth factor that encourages the production of white blood cells in the bone marrow. The body is protected from infections by these cells.
Emgrast M 500mcg Injection is administered intravenously by a licensed medical practitioner. Your doctor will determine the appropriate dosage and frequency of administration for you. This is based on the condition you are being treated for and is subject to change.
USES OF RECOMBINANT HUMAN (EMGRAST-M) INJECTION
- Prevention of Infections after chemotherapy
WORKS OF RECOMBINANT HUMAN (EMGRAST-M) INJECTION
A growth factor called Emgrast M 500mcg Injection encourages the bone marrow to create white blood cells. The body is protected from infections by these cells.
SIDE EFFECTS OF RECOMBINANT HUMAN (EMGRAST-M) INJECTION
- Bone pain
- Decreased blood pressure
- Feeling of discomfort
- Flushing (sense of warmth in the face, ears, neck, and trunk)
- Flu-like symptoms
WARNING & PRECAUTIONS
The ability to drive may be affected by Emgrast M 500mcg Injection, although this is unknown. If you encounter any symptoms that impair your focus or reaction time, avoid operating a vehicle.
Use of Emgrast M 500mcg Injection during pregnancy may be dangerous. Despite the paucity of human research, studies on animals have indicated negative consequences on the growing fetus. Before giving you a prescription, your doctor will consider the advantages and any possible hazards. Please speak with your physician.
It is probably safe to take Emgrast M 500mcg Injection while breastfeeding. Inferred from scant human evidence, the medicine does not appear to pose a major risk to the developing fetus.